Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)

• Status: Completed
• Trial end date: 2016-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Study Phase: phase 1 and phase 2

Objective: Evaluation of the effect of lenalidomide, cyclophophamide and prednisone (REP) in patients with relapsed multiple myeloma previously treated with lenalidomide

Study design: prospective, multicenter, non-randomized

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UMC Utrecht
• Collaborator: Celgene Corporation
• Treatments: Cyclophosphamide; Lenalidomide; Prednisone; Thalidomide

Criteria

Inclusion Criteria:

• salmon & Durie stage II/III A or B

• previous lenalidomide refractory disease

• patient commits to pregnancy prevention programme

Exclusion Criteria:

• non-secretory myeloma

• known hypersensitivity to lenalidomide

• inadequate marrow reserve